## Edgar Filing: ACADIA PHARMACEUTICALS INC - Form 4

ACADIA PI Form 4 March 24, 2	HARMACEUTIC	CALS INC	2								
FORM	ΠД								PPROVAL		
	UNITED	STATES		RITIES A shington			COMMISSION	N OMB Number:	3235-028	7	
Check th if no lon subject to Section 2 Form 4 c Form 5	ger o <b>STATEN</b> 16. or			SECU		WNERSHIP OF	Estimated burden ho response	urs per	5		
obligatio may con See Instr 1(b).	tinue. Section 17(	a) of the I	Public U	Itility Hol	ding Cor		nge Act of 1934, of 1935 or Section 940				
(Print or Type	Responses)										
1. Name and A Moore Terr	Person <u>*</u>	2. Issuer Name <b>and</b> Ticker or Trading Symbol				5. Relationship of Reporting Person(s) to Issuer					
			ACADIA PHARMACEUTICALS INC [ACAD]				(Check all applicable)				
(Last)	Middle)	3. Date of Earliest Transaction (Month/Day/Year)				Director 10% Owner   Officer (give title Other (specify below)					
SUITE 300	LEY CENTRE D	RIVE,	03/20/2	2015			EVP, CHIEF	COMMERCIA	LOFFICER		
		4. If Amendment, Date Original Filed(Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person					
SAN DIEG	O, CA 92130							More than One R			
(City)	(State)	(Zip)	Tab	ole I - Non-I	Derivative	Securities A	cquired, Disposed	of, or Beneficia	lly Owned		
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		Date, if	3. Transactio Code (Instr. 8) Code V	Disposed (Instr. 3, 4	(A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
Reminder: Rep	port on a separate line	e for each cla	ass of sec	urities bene	ficially ow	ned directly	or indirectly.				
					inforn requi	nation cont red to response ays a current	spond to the colle tained in this form ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)		
	Tab					posed of, or convertible	Beneficially Owned securities)	d			

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities

## Edgar Filing: ACADIA PHARMACEUTICALS INC - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	Securities Acquired (A Disposed of (Instr. 3, 4, 5)	f (D)	(Month/Day/Year)		(Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 34.45	03/20/2015		A	120,000		<u>(1)</u>	03/19/2025	Common Stock	120,000
Reporting Owners										
<b>Reporting Owner Name / Address</b>			Director	10% Owr	er Officer	Rela	ationships		Othe	r.

EVP, CHIEF COMMERCIAL

**OFFICER** 

Moore Terrence O 3611 VALLEY CENTRE DRIVE, SUITE 300 SAN DIEGO, CA 92130

## Signatures

/s/ Glenn F. Baity, Attorney-in-Fact 03/24/2015

<u>\*\*</u>Signature of Reporting Person

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Date

(1) 25% of the shares subject to the Stock Option vest and become exercisable on March 20, 2016. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.